News
CardioGenics Holdings Inc. Announces Completion of Cartridge Design for QL Care Analyzer
MISSISSAUGA, Ontario, - January 27, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the in-vitro diagnostics segment of the Point-Of-Care (POC) diagnostic market, announced today that it has completed the design of the self-metering cartridge for its POC diagnostic device, the QL Care Analyzer.The company has also filed a patent application regarding the self-metering cartridge.
read more
CardioGenics Holdings Inc. Featured in Medical Device Daily
MISSISSAUGA, Ontario, - November 13, 2009 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the immunoassay segment of the IVD testing market, was featured in Medical Device Daily's November 12, 2009 edition.
read more
CardioGenics Holdings Inc. Announces Letter To Shareholders
Mississauga, Ontario, - October 27, 2009 - CardioGenics Holdings Inc. (OTCBB: CGNH), a developer of technology and products targeting the immunoassay segment of the In-Vitro Diagnostic (IVD) testing market, has issued a letter to its shareholders. To view the letter in its entirety, please visit the following link: http://irgnews.com/node/1633.
read more
CardioGenics Holdings Inc. Announces Name, Ticker Symbol and CUSIP Number Change.
Mississauga, Ontario, October 26, 2009 - CardioGenics Holdings Inc. (OTC Bulletin Board: JAGH) has received notification from FINRA that the name and ticker symbol change for the Company on the OTCBB will take place at the beginning of business on Tuesday, October 27, 2009.
read more
Company Name Changed to CardioGenics Holdings Inc.
Mississauga, Ontario, October 2, 2009 - JAG Media Holdings, Inc. (OTCBB: JAGH) filed with the Secretary of State of Nevada yesterday a certificate of amendment to its Articles of Incorporation, which changed the Company's name to CardioGenics Holdings Inc., to better reflect its new business direction following its acquisition of CardioGenics Inc., and increased the Company's authorized common shares from 500,000,000 to 650,000,000.
read more
